Tempest Therapeutics jumps on positive combo therapy liver cancer trial data

Tempest Therapeutics

11/10/2023 14:22

** Shares of cancer-focused drug developer Tempest
Therapeutics Inc  TPST.O  up 666.7% at $1.84 premarket
    ** Co says its experimental treatment TPST-1120 in
combination showed clinical superiority in multiple early- to
mid-stage study goals to treat the most common type of liver
cancer 
    ** The trial tested TPST-1120 in combination with Roche's
 ROG.S  atezolizumab and bevacizumab in a randomized comparison
to atezolizumab + bevacizumab (control arm) in the first-line
treatment of patients
    ** Confirmed objective response rate of 30% for the
TPST-1120 triplet arm vs 13.3% for the control arm 
    ** TPST-1120 remains well tolerated, with safety data
comparable between the two arms - company
    ** Roche managed the study operations for this multicenter
trial, pursuant to a clinical collaboration; Tempest retains all
product rights to TPST-1120 
    ** Tempest separately also reported that its board has
adopted a limited duration stockholder rights plan, effective
immediately
    ** As of last close, stock down ~79% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))